Cardiac cell-based therapy has emerged as a novel therapeutic option for patients dealing with untreatable refractory angina (RA). However, after more than a decade of controlled studies, no definitive consensus has been reached regarding clinical efficacy. Although positive results in terms of surrogate endpoints have been suggested by early and phase II clinical studies as well as meta-analyses, the more recent reports lacked the provision of definitive response in terms of hard clinical endpoints. Regrettably, pivotal trials designed to conclusively determine the efficacy of cell-based therapeutics in such a challenging clinical condition are therefore still missing. Considering this, a comprehensive reappraisal of cardiac cell-based therapy role in RA seems warranted and timely, since a number of crucial cell- and patient-related aspects need to be systematically analysed. As an example, the large variability in efficacy endpoint selection appears to be a limiting factor for the advancement of cardiac cell-based therapy in the field. This review will provide an overview of the key elements that may have influenced the results of cell-based trials in the context of RA, focusing in particular on the understanding at which the extent of angina-related endpoints may predict cell-based therapeutic efficacy.

1. Introduction

Refractory angina (RA) is a chronic condition characterized by the presence of persistent angina or angina equivalents (≥3 months) caused by untreatable coronary artery disease (CAD) in patients with objective evidence of myocardial ischemia [1]. The presence of left ventricular (LV) dysfunction may worsen such a clinical scenario. Refractory angina patients are defined as being “no option” since they are deemed not amenable for conventional revascularization treatment for reasons related to diffuse coronary lesions, unsuitability to chronic total occlusion mechanical revascularization, or frailty from the presence of severe comorbidities. These pathological features may significantly affect the quality of life with regard to physical function and well-being as well as midterm fatality [2], although the most recent reports have documented a time-dependent increase in mortality rates (less than 4% at 1 year and 30% at 9 years) [3]. Outcome ameliorations have been ascribed to rigorous adoption of standard medical therapy, risk factor modification, and aggressive revascularization techniques [4]. Nevertheless, despite continuous advances in CAD management, particularly in the aged population, the number of patients suffering from RA and the correlated hospitalization costs are still growing [5]. In fact, available estimates suggest that RA affects between 600,000 and 1.8 million people in the USA with an incidence of 50,000 [5] and 30,000–50,000 new cases per year in the USA and continental Europe, respectively [6].
It is important to highlight that the medical care of these patients is particularly challenging. As a matter of fact, the therapeutic options and available directions from current guidelines are still limited [6]. Moreover, the interaction between clinical symptoms, myocardial perfusion abnormalities, coronary anatomy, and ventricular function are particularly complex in these individuals. Thus, novel treatments for RA management in patients nonresponsive to standard pharmacologic therapies and not amenable to mechanical revascularization procedures are evermore needed.

In this regard, recent efforts have been directed on the discovery of novel therapies based on innovative interventional techniques, neuremodulation, shockwave strategies, and cell-based interventions. In particular, in the analogy of other high-impact cardiac conditions as left ventricular dysfunction following ST-elevated acute myocardial infarction and chronic heart failure, cardiac cell-based therapy has emerged as a promising tool for the management of RA [7]. The application of cardiac cell-based therapy in this patient population was described for the first time in 2003 by Tse and coworkers [8]. After this preliminary experience, several uncontrolled and controlled phase I-II trials were conducted. Collectively, published studies have overtime demonstrated the safety and potential benefit of different cell types. In an attempt to shed light on the available results, 3 meta-analyses have specifically addressed cardiac cell-based therapy efficacy in RA [9–11]. Notably, the most recent work by Khan et al. [11], cumulatively taking into account 6 controlled trials with 365 enrolled patients, clearly showed that cardiac cell-based therapy has had a positive impact over standard of care in terms of myocardial perfusion, angina frequency, use of antianginal medications, change in the Canadian functional class, exercise tolerance, LV function, and major adverse cardiac events (MACE). Notably, 3 large rigorous clinical trials have been recently made available [12–14]. Unfortunately, the outcomes reported in these studies were not conclusive due to early discontinuation, for example, the regrettable decision on the behost of the study sponsor to prematurely stop the phase III RENEW trial which was sufficiently powered to definitively evaluate the safety and efficacy of intramyocardial injection of CD34+ cells in “no option” RA patients.

In the light of these and other inconclusive results [15, 16], a reappraisal of the therapeutic efficacy of cardiac cell-based therapy in RA seems imperative. In particular, a number of crucial aspects, including rigorous trial design, sample size, and endpoint assumptions, deserve to be carefully reconsidered. As an example, the huge discrepancy in the choice of endpoints probably represents the more relevant limiting factor for the lack of efficacy demonstration.

In this work, we have provided an updated overview of the results stemmed from available clinical trials focused on the role of cardiac cell-based therapy for the management of RA. Furthermore, we have comprehensively discussed ischemia-related outcomes, including objective and subjective endpoints, in order to facilitate a critical reappraisal of published studies on cardiac cell-based therapy for RA.

2. Overview of Cardiac Cell-Based Therapy Clinical Trials in RA

To date, twenty-six cell-based therapy trials have been conducted in the context of RA (see Table 1). Key aspects, including the number of patients treated, cell sources and types, baseline ejection fraction, delivery methods, and efficacy and safety outcomes, have been collected and analysed hereafter. As for the concomitance of LV dysfunction, when available, baseline EF below normal and/or the proportion of patients with LV impairment has been highlighted.

It is worth to mention that safety of cardiac cell-based therapy, defined as related serious adverse events (SAEs) and/or major adverse cardiac events (MACE) occurring during cell delivery, hospitalization, and follow-up, appears to be overall reassuring as for available studies.

2.1. Study Design. A significant proportion of published trials (n = 13) may be categorized as uncontrolled pilot or phase I studies that cumulatively enrolled 220 patients (21% of the entire accrual population), ranging from a minimum of 4 to a maximum of 38 subjects [8, 19–23, 26, 28, 29, 31, 33, 36, 39]. A total of 841 patients have been included in phase II randomized controlled trials (RCTs; n = 13) [12–17, 24, 30, 32, 34, 35, 40, 41]. The vast majority of these RCT reported the adoption of an appropriate placebo or saline group [13, 14, 17, 30, 34, 35, 38, 41, 42]. However, some other studies (for instance FOCUS-HF and PROGENITOR trials), in an attempt to overcome ethical and practical obstacles of a placebo group, employed alternative methodologies such as sham and mock injection procedures [15, 24]. To our knowledge, large confirmatory phase III studies are not yet available. The mean follow-up was 12 months (range: 3–36 months). Merely 23% of studies were able to prolong postoperative surveillance beyond 1 year.

2.2. Cell-Related Variables. Selected or unfractioned cells, primarily derived from the bone marrow (BM) [8, 13, 16, 19–24, 26, 28–33, 35, 36, 39–41] and to a lesser extent from peripheral blood (PB) [15, 17, 38] and, more recently, from the adipose tissue (AT), have been tested for their therapeutic potential in RA [14, 34]. Specifically, mononuclear cells (MNC), endothelial progenitor cells (such as CD34+ and CD133+ cells), and mesenchymal cells (MSC) have been subsequently investigated (Figure 1). It is worth highlighting that a direct comparison of different cell types is unfortunately not available. Notably, BM-derived MNC, the most extensively delivered cell type, have an unambiguously proven safety profile in the early and long-term period. Available data further suggested that BM-MNC therapy seemed effective in ameliorating myocardial perfusion and angina frequency [31, 42]. Moreover, the group of Mann et al. [31] showed that repeated BM cell injections in previously responding patients can reinforce clinical improvements. To date, such “first generation” cell lines have not been followed by more advanced “next generation” cell therapeutics. For instance, allogeneic applications, which have provided positive outcomes for other pathologic cardiac conditions [43–45], have not yet been explored in RA to date.
| Trial                  | Design          | Treated/controls | Baseline LVEF% | Cell type | Delivery | FU (months) | Efficacy outcomes                                                                 | Safety                                                                 |
|-----------------------|-----------------|------------------|----------------|-----------|----------|-------------|----------------------------------------------------------------------------------|-----------------------------------------------------------------------|
| ACT34-CMI [17, 18]    | RCT, Phase II, dose finding | 111/56           | Normal         | PB-CD34⁺ | IM⁺endo  | 6/12/24     | ↓ CCS and NTG use ↓ angina frequency in the low-dose group only ↑ perfusion ↑ exercise capacity in the low-dose group only | No differences, cell therapy versus control groups                     |
| Adler et al. [19]     | Phase I, dose finding | 9/0              | Normal         | BM-CD133⁺ | IC       | 24          | ↔ angina frequency ↑ perfusion ↓ CCS and NYHA ↔ perfusion ↑ MVO₂ ↔ LVEF, LVEDV, and LVESV | No MACE reported                                                      |
| ATHENA ATHENA II [14] | RCT, phase II, dose finding | 17/14            | 31.1 ± 8.2%    | AT-MSC   | IM⁺endo  | 12          | No differences, cell therapy versus controls groups                               |                                                                        |
| Babin-Ebell et al. [20]| Phase I          | 6/0              | 66.67% of patients < 50% | BM-CD133⁺ | IM⁺pi   | 3/6/12      | ↓ CCS ↔ LVEF ↓ CCS, angina frequency, and NTG use ↑ perfusion ↑ MVO₂ ↔ LVEF, LVESV, and LVESV | 1 possible cell related death                                          |
| Beeres et al. [21]    | Phase I          | 25/0             | 47% ± 13%      | BM-MNC   | IM⁺endo  | 3/6/12      | 1 not cell therapy-related death and 1 MACE, 1 SAE                             |                                                                        |
| Briguori et al. [22]  | Phase I          | 10/0             | 30% of patients < 50% | BM-MNC   | IM⁺endo  | 12          | ↓ CCS, angina frequency ↑ perfusion ↓ CCS, angina frequency ↑ perfusion ↑ treadmill exercise ↔ LVEF | 1 not cell therapy-related MACE                                      |
| Fuchs et al. [23]     | Phase I          | 27/0             | 48 ± 9%        | BM-MNC   | IM⁺endo  | 3/12        | 1 cell therapy-related periprocedural SAE (aortic dissection) 3 not cell therapy-related MACE at follow-up |                                                                        |
| FOCUS-HF [24]         | RCT, phase II    | 20/10            | 37 ± 10.6% cell therapy group, 39 ± 9.1% control group | BM-MNC   | IM⁺endo  | 3/6         | SAEs evenly distributed between control and cell therapy groups                 |                                                                        |
| FOCUS-CCTRN [16]      | RCT, phase II    | 61/31            | 34.7 ± 8.8% cell therapy group, 32.3 ± 8.6% control group | BM-MNC   | IM⁺endo  | 6           | No significant differences between control versus cell therapy groups           |                                                                        |
| Haack-Sørensen et al. [25–27] | Phase I          | 31/0             | Normal         | BM-MSC   | IM⁺endo  | 12/36       | Not cell therapy-related SAEs and MACE                                          |                                                                        |
Table 1: Continued.

| Trial                     | Design                     | Treated/controls | Baseline LVEF% | Cell type | Delivery | FU (months) | Efficacy outcomes | Safety                          |
|---------------------------|----------------------------|------------------|----------------|-----------|----------|-------------|--------------------|--------------------------------|
| Klein et al. [28]         | Phase I                    | 10/0             | 15.8 ± 5       | BM-CD133* | IM^spi   | 9           | ↓ CCS             | 1 possible cell therapy-related death |
|                           |                            |                  |                |           |          |             | ↑ LVEF, LVEDV      |                                |
|                           |                            |                  |                |           |          |             | ↓ CCS and NYHA    |                                |
|                           |                            |                  |                |           |          |             | ↔ perfusion        |                                |
|                           |                            |                  |                |           |          |             | ↑ LVEF, LVEDV,    |                                |
|                           |                            |                  |                |           |          |             | and LVESV          |                                |
| Lee et al. [29]           | Phase I, dose finding      | 38/0             | Normal         | PB-CD34*  | IC       | 6/9/12      | ↓ CCS             | 2 not cell therapy-related deaths |
|                           |                            |                  |                |           |          |             | ↓ CCS and NYHA    |                                |
|                           |                            |                  |                |           |          |             | ↑ perfusion        |                                |
|                           |                            |                  |                |           |          |             | ↑ LVEF, LVEDV,    |                                |
|                           |                            |                  |                |           |          |             | and LVESV          |                                |
| Losordo et al. [30]       | RCT, phase II, dose finding| 18/6             | NA             | PB-CD34+  | IM^fdo   | 3/6/9/12    | ↓ CCS, angina frequency, NTG use | SAEs evenly distributed between control and cell therapy groups |
|                           |                            |                  |                |           |          |             | ↑ perfusion        |                                |
|                           |                            |                  |                |           |          |             | ↑ exercise capacity |                                |
|                           |                            |                  |                |           |          |             | ↑ exercise capacity |                                |
|                           |                            |                  |                |           |          |             | ↑ exercise capacity |                                |
|                           |                            |                  |                |           |          |             | ↑ LVEF             |                                |
| Mann et al. [31]          | Phase I                    | 23/0             | Normal         | BM-MNC    | IM^fdo   | 3/6/12      | ↓ CCS, angina frequency | No safety issues               |
|                           |                            |                  |                |           |          |             | ↑ perfusion        |                                |
|                           |                            |                  |                |           |          |             | ↑ perfusion        |                                |
|                           |                            |                  |                |           |          |             | ↑ exercise capacity |                                |
|                           |                            |                  |                |           |          |             | ↑ LVEF             |                                |
| Pokushalov et al. [32]    | RCT, Phase II              | 55/54            | 27.8 ± 3.4%    | BM-MNC    | IM^fdo   | 3/6/12      | ↓ CCS, NYHA, angina frequency and NTG use | Significant difference in mortality rate between cell therapy versus control groups (6 versus 21 deaths, resp.) |
|                           |                            |                  | 26.8 ± 3.8%    |           |          |             | ↑ perfusion        |                                |
|                           |                            |                  | control group  |           |          |             | ↑ perfusion        |                                |
|                           |                            |                  |                |           |          |             | ↑ exercise capacity |                                |
|                           |                            |                  |                |           |          |             | ↑ LVEF             |                                |
| Pompilio et al. [33]      | Phase I                    | 5/0              | 40% of patients < 50% | BM-CD133* | IM^spi   |             | ↓ CCS, angina frequency | No safety issues               |
|                           |                            |                  |                |           |          |             | ↑ perfusion        |                                |
|                           |                            |                  |                |           |          |             | ↔ LVEF             |                                |
|                           |                            |                  |                |           |          |             | ↔ perfusion        |                                |
|                           |                            |                  |                |           |          |             | ↔ exercise capacity |                                |
|                           |                            |                  |                |           |          |             | ↑ LVEF             |                                |
| PRECISE [34]              | RCT, phase II              | 21/6             | 36.7 ± 7.5%    | AT-MSC    | IM^fdo   | 6/12/18     | ↑ MVO2 and MET     | SAEs evenly distributed between control and cell therapy groups |
|                           |                            |                  | 34.2 ± 9.5%    |           |          |             | ↔ LVEF             |                                |
|                           |                            |                  | control group  |           |          |             | ↑ LVEF             |                                |
|                           |                            |                  |                |           |          |             | ↑ LVEF             |                                |
|                           |                            |                  |                |           |          |             | ↑ LVEF             |                                |
| PROGENITOR [15]           | RCT, phase II              | 19/9             | Normal         | PB-CD133* | IM^fdo   | 6/12/24     | ↑ LV mass and LVWMI | SAEs and MACE evenly distributed between control versus cell therapy groups |
|                           |                            |                  |                |           |          |             | ↔ CCS, angina frequency and NTG use |                                |
|                           |                            |                  |                |           |          |             | ↑ perfusion        |                                |
|                           |                            |                  |                |           |          |             | ↑ treadmill exercise |                                |
|                           |                            |                  |                |           |          |             | ↑ LVEF             |                                |
|                           |                            |                  |                |           |          |             | ↑ LVEF             |                                |
| PROTECT-CAD [35]          | RCT, phase II, dose finding| 19/9             | 51.9 ± 8.5%    | BM-MNC    | IM^fdo   | 3/6         | ↑ NYHA            | 1 death and 1 MACE in control group |
|                           |                            |                  | 45.7 ± 8.3%    |           |          |             | ↔ perfusion        |                                |
|                           |                            |                  | control group  |           |          |             | ↑ treadmill exercise | 1 SAE in cell therapy group at follow-up |
|                           |                            |                  |                |           |          |             | ↑ LVEF             |                                |
|                           |                            |                  |                |           |          |             | ↔ LVEF, LVEDV and LVESV |                                |
Table 1: Continued.

| Trial               | Design | Treated/controls | Baseline LVEF% | Cell type | Delivery | FU (months) | Efficacy outcomes                                                                 | Safety                                                                 |
|---------------------|--------|------------------|----------------|-----------|----------|-------------|-----------------------------------------------------------------------------------|------------------------------------------------------------------------|
| ReACT [36, 37]      | Phase I| 14/0             | Normal         | BM-MNC    | IM \(^{\text{mp}}\) | 3/6/12      | ↓ CCS, ↑ perfusion, ↔ perfusion, ¶ LVEF                                          | 2 deaths (1 for cardiogenic shock due to MI, 1 MI)                      |
| RegentVsel [13]     | RCT, phase II | 16/15         | Normal         | BM-CD133\(^{+}\) | IM \(^{\text{endo}}\) | 4/12        | ↔ CCS and NTG use, ↔ perfusion, ¶ LV volumes, ↑ LV volumes                        | MACE evenly distributed between control versus cell therapy groups    |
| RENEW [12, 38]      | RCT, phase II | 57/55         | Normal         | PB-CD34\(^{+}\) | IM \(^{\text{endo}}\) | 3/6/12      | ↓ angina frequency, ↑ exercise capacity, ↔ angina frequency and NTG, ↑ LVEF      | 1 SAE in cell therapy group (pseudoaneurysm of the femoral artery)    |
| Tse et al. [8]      | Phase I | 8/0             | Normal         | BM-MNC    | IM \(^{\text{endo}}\) | 3           | ↑ perfusion, ↔ LVEF, ↑ target wall thickening and motion                        | No MACE reported                                                       |
| Tuma et al. [39]    | Phase I | 14/0             | 31.2%          | BM-MNC    | IV       | 24          | ↓ CCS, angina frequency, ↑ perfusion, ↑ exercise capacity, ↑ LVEF, ↓ CCS        | No safety issues                                                       |
| van Ramshorst et al. [40] | RCT, phase II | 25/25         | Normal         | BM-MNC    | IM \(^{\text{endo}}\) | 3/6        | ↑ perfusion, ↔ LVEF, ↑ exercise capacity ↔ LVEDV and LVESV, ↓ CCS, angina frequency, ↑ perfusion, ↑ exercise capacity | MACE and SAEs evenly distributed between control versus cell therapy groups |
| Wang et al. [41]    | RCT, phase II | 56/56           | NA             | BM-CD34\(^{+}\) | IC       | 3/6        | No significant differences between control versus cell therapy groups          | No significant differences between control versus cell therapy groups |

AT: adipose tissue; BM: bone marrow; CABG: coronary artery bypass grafting; FU: follow-up; LVEDV: left ventricular end-diastolic volume; LVEF: left ventricular ejection fraction (normal EF defined as ≥50%); LVESV: left ventricular end-systolic volume; LV WMI: left ventricular wall motion index; MACE: major adverse cardiac events; MET: maximal metabolic equivalent; MI: myocardial infarction; MNC: mononuclear cells; MSC: mesenchymal cells; NA: not available; NTG: nitroglycerin; PB: peripheral blood; PCI: percutaneous coronary intervention; RCT: randomized controlled trial; RWM: regional wall motion; SAEs: serious adverse events.
Likewise, the so-called “second generation” stem cells, consisting of more purified cell populations, such as cardiac stem cells (CSC), cardiosphere-derived cells, or combination of cells (MSC/CSC or MSC/macrophage lineages), have not yet been examined in RA. Cumulatively, the big picture of on-going studies suggests that new early studies are still pursuing the path of autologous BM-MNC (Figure 1).

As for cell dose, unlike other cardiac settings, it has to be mentioned that there is a plethora of dose-escalation trials already available [14, 17–19, 29, 30, 35]. Most of these studies concerned PB-derived CD34+ cell dose finding, thanks to the effort of Losordo and coworkers [30]. Once verified in early safety of intramyocardial injection of 50,000 CD34+ cells/kg, in the subsequent phase IIb ACT34-CMI study, they compared the efficacy of two escalating dosages of CD34+ cells (1 × 10⁷ and 5 × 10⁷). Surprisingly, patients treated with the low dosage experienced greater improvements in angina frequency and exercise tolerance at 6 and 12 months, [17]. Nevertheless, after 24 months of follow-up, reduction in angina frequency was equivalent in both cell groups (p = 0.03) [18]. Additionally, Lee et al. [29] recently reported the superiority of 1 × 10⁷ cells with respect to 3 × 10⁶ CD34+ cells in improving heart function and clinical symptoms in patients with untreated myocardial ischemia and LV dysfunction.

The dose-dependent response of BM-MNC has been further investigated in the PROTECT-CAD study [35] in which, however, no significant difference between the low- (1 × 10⁶ cells/0.1 mL) and the high-dose groups (2 × 10⁶ cells/0.1 mL) was observed in terms of total exercise time at 6 months of follow-up compared to baseline.

Therefore, based on currently available studies, there is no clear evidence of a dose-dependent effect of BM-derived cell delivery in RA patients. Further studies are thus necessary to completely address this question.

2.3. Cell Delivery. The injection technique is certainly a critical factor for the success and optimization of cell therapeutics. To date, a noticeable proportion of cardiac cell-based therapy trials in RA (n = 18) utilized advanced catheter-based endocavitary transcatheter cell administration strategy [8, 13–17, 21–26, 30–32, 34, 35, 38]. In this regard, the NOGA electromechanical mapping system has been proposed as an effective and reliable percutaneous method capable of discriminating between viable myocardium and scar tissue to precisely guide cell delivery into the target territories of the left ventricle. On the other hand, the fluoroscopy-guided strategy brings cost advantages and wider accessibility. In both cases, procedural safety has been consistently confirmed. Recently, in the context of the Phase I Trial of Endocavitary Injection of Bone Marrow Derived CD133+ Cells in Ischemic Refractory Cardiomyopathy (RECARDIO trial, NCT02059681), we have proposed a novel approach based on the integration of 3-dimensional (3-D) electroanatomical mapping (CARTO) with real-time intracardiac echocardiography (ICE) to guide the fluoroscopy-based infusion catheter [46].

Other delivery approaches included intracoronary [19, 29, 41] and intravenous infusion [39] and direct epicardial injection by open-chest surgery [20, 28, 33, 36]. Although no comparative studies are available to ascertain the most effective delivery option in RA, it appears that intramyocardial cell inoculation was by far the preferred delivery method in such a clinical context.

2.4. Efficacy Outcomes. A wide spectrum of surrogate efficacy endpoints has been proposed to evaluate the efficacy of cell therapy in the RA setting, including indices of angina severity (Figure 2), as well as myocardial perfusion, exercise capacity, and cardiac function evaluations (Figure 3).

2.4.1. Angina Assessment. As for the assessment of angina, the Canadian Cardiovascular Society (CCS) classification score (Figure 2(a)) was employed in the vast majority of available studies (n = 23). Notably, 78% of these trials reported a significant improvement in CCS angina class after cardiac cell-based therapy. Importantly, 24% of trials have described an improvement of CCS greater than 2 classes in cell-treated patients (Figure 2(b)). As an example, the randomized, placebo-controlled trial by Wang and coworkers [41] has described a remarkable reduction in CCS class from 3.3 ± 0.5 at baseline to 0.9 ± 1.0 at 6 months after intramyocardial delivery of CD34+ cells.

As an alternative evaluation, the number of anginal episodes per week as well as nitroglycerin (NTG) consumption has been proposed as valuable efficacy endpoints to describe changes in angina severity. Remarkably, in line with changes observed in CCS class, almost all studies reported a significant improvement in angina frequency and antianginal medications (Figures 2(c) and 2(d)). In this regard, the ACT34-CMI trial [17] suggested positive outcome benefits lasting over 2 years following intramyocardial administration of BM-derived CD34+ cells [18].

2.4.2. Quality of Life and Health Status Evaluation. Patients’ quality of life and health status have been investigated as pertinent variables strictly associated with angina severity.

Figure 1: Cell types applied in clinical trials to treat RA. The figure depicts the number of published studies sorted for cell types and trial phases. MNC: mononuclear cells; MSC: mesenchymal stem cells; CD: cluster of differentiation.
By the use of dedicated surveys, many studies documented a positive impact of cardiac cell-based therapy in terms of quality of life improvements. For instance, the FOCUS-HF trial adopted the Minnesota Living with Heart Failure and the Short Form-36 questionnaires to evaluate at 6 months over baseline the quality of life improvements in cell-treated and control patients [24]. In both questionnaires, patient scores improved only in the cell-treated group ($p = 0.009$ and $p = 0.002$, resp.). Other studies documented the changes in the quality of life using the disease-specific Seattle Angina Questionnaire (SAQ). Consistently, both Henry et al. [18] and van Ramshorst et al. [40] showed a significant increase in SAQ scores in these patients at 6 and 12 months.

### 2.4.3. Myocardial Perfusion Assessment

Changes in regional myocardial perfusion were usually assessed by single-photon emission computed tomography (SPECT) imaging, with the aim to provide semiquantitative scores of the severity and extent of the perfusion defect. Specifically, changes in summed stress score (SSS), summed rest score (SRS), and summed difference score (SDS) were measured between the ends of follow-up and baseline. Remarkably, 24 out of 26 analysed trials were able to report a SPECT perfusion endpoint (Figure 3(a)). Overall, a significant percentage of studies (58%) suggested that the therapeutic delivery of cells leads to an objective improvement in myocardial perfusion. It is however worth mentioning that a considerable proportion of positive outcomes stemmed from uncontrolled phase I trials which enrolled a limited number of patients [8, 19–23, 31, 33, 36, 39]. Convincingly, positive data were also reported by more rigorous RCT [17, 40, 41], including the ACT34-CMI trial [17], which showed at 6 months of follow-up a significant improvement of the SSS in the cell group but not in controls ($-117.4 \pm 221.2$ versus $+0.1 \pm 161.1$, $p = 0.002$). Conversely, disappointing findings arose from the recently published REGENT-VSEL [13] and ATHENA trials [14]. The latter randomized, double-blind study that enrolled in 1:1 ratio 31 patients versus controls failed to uncover statistical significant differences in SPECT parameters. Taken together, these findings suggest the need for an implementation and standardization of alternative methodologies, including positron emission computed tomography (PET) or cardiac magnetic resonance (cMR) imaging, to definitively document changes in regional and global myocardial perfusion at a microvascular level [17, 41].

### 2.4.4. Functional Capacity Evaluation

As for functional capacity assessments, various objective endpoints were proposed, taking advantage of exercise testing with or without ventilatory gas exchange measurements. A variety of indicators was analysed, including exercise time, walking distance, maximal O$_2$ consumption (MVO$_2$), and other metabolic equivalents (METs). Cumulatively, such surrogate endpoints were reported to be positive in the majority of RCT, including the PROTECT-CAD [35], ACT34-CMI [17], ATHENA [14], and RENEW [12] trials (Figure 3(b)). In particular,
the RENEW trial [38], the larger phase III study comparing intramyocardial delivery of CD34+ cells with respect to two control groups (placebo and standard care), was designed to detect changes in total exercise time (TET) at 12 months in 400 untreatable RA patients. Although the enrolment was prematurely stopped by the sponsor after the first 112 patients, study results, made recently available [12], showed the superiority of the cell therapy-treated patients compared with controls in improving TET (139 s ± 115 versus 69 s ± 122 s; \( p = 0.01 \)). On the contrary, two consecutive reports by Perin et al. [16, 24] described the lack of MVO2 improvements in patients receiving BM cell therapy versus placebo, with the exception of a young patient subset (≤60 years). However, functional findings described here, when taken cumulatively, should be examined with caution since possible shortcomings, such as a wide heterogeneity of endpoints and the intrinsic limitations of such functional tests (e.g., subject compliance, orthopedic, or lower limb deficiencies), may have conditioned the outcomes.

Nevertheless, along with angina-related and perfusion endpoints, functional capacity assessments may play an important role in the context of future cardiac cell-based therapy studies in RA. Much effort should be given to the methodology for isolating improvements as well as for sample size selection. In this regard, from a methodological and regulatory standpoint, it is valuable to note that the mindful and weighted combination of the aforementioned indicators may offer a unique opportunity to provide efficacy evidence with relatively limited patient sample sizes.

2.4.5. Global and Regional Cardiac Function Assessment. Cardiac cell-based therapy effects have been assessed by measuring global and regional cardiac function before and after cell administration. A variety of imaging methodologies with different acquisition and analysis protocols was applied. In the RA setting, left ventricular ejection fraction (LVEF) and volumes were assessed by cMR in 7 studies [8, 13, 28, 31, 34, 35, 40], by echocardiogram in 6 studies [14, 16, 22, 32, 33, 37], by SPECT in 4 studies [21, 23, 26, 39], and by combining different modalities in further 4 studies [15, 20, 24, 29]. In regard to LVEF changes, a significant number of studies (52%) revealed a lack of improvements at different follow-up time points (Figure 3(c)) [8, 13–15, 22–24, 31, 33, 34, 36]. In particular, when limiting the analysis to cMR evaluations, the majority of published studies were negative [8, 13, 28, 31, 34, 35, 40], with the exceptions of the PROTECT-CAD trial [35] that demonstrated at 6 months a significant improvement in global LVEF in BM-treated patients (\( p = 0.044 \)) versus controls. Additionally, the study by van Ramshorst et al. [40] confirmed at 3 months an increase in LVEF in the cell-treated group only (change, 3%; 95% CI, 0.5% to 4.7% versus –1%; 95% CI, −2.1 to 1.1; \( p = 0.03 \)).

In accordance with LVEF findings, a large proportion of studies (62%) also reported negative outcomes associated with LV volume measurements (Figure 3(d)). Cumulatively, these data confirm the well-known assumption that the presence of a recovering ischemic (hibernating) myocardium after perfusion restoration is achievable in a minority of RA patients.
3. Future Perspectives

Is there a chance for cardiac cell-based therapy to be approved as a new therapy for RA? Overall, although extremely demanding, RA is undoubtedly, among cardiac conditions, the one in which cardiac cell-based therapy has shown very promising outcomes. Indeed, a consistent body of published trials cumulatively indicated that, although hard clinical endpoint has not been reached so far, cardiac cell-based therapy may increase the functional/perfusion status in a subset of RA patients as well as in a vast proportion of the quality of life, significantly reducing angina symptoms and antiangina medication usages.

Consistently, meta-analyses published to date showed that cardiac cell-based therapy has a clinically relevant impact over standard care [9–11]. Unfortunately and importantly, pivotal trials have failed to provide a definitive response so far, essentially due to strategically driven discontinuation of patient recruitment before reaching the prespecified sample size [12], low enrolment rates [13], or safety concerns [14]. Despite this, given the paucity of effective therapeutics, along with the extremely demanding clinical need, we consider cardiac cell-based therapy has a viable treatment option in RA for an addition to the therapeutic armamentarium of invasive cardiologists. It is worth noting that, using autologous BM-derived cells, intramyocardial cell delivery has been recently cleared for hospital-based reimbursement (Heart Centrum Leiden, Netherlands) as a percutaneous therapeutic strategy in the context of RA (code 979001088).

3.1. Novel Cell Types and Allogeneic Setting. Interestingly, alternative cell therapeutics and “off-the-shelf” settings are currently under investigation to overcome hurdles related to the lack of potency and cell impairments due to age and risk factors. For example, the “Safety and Efficacy of Human Umbilical-Cord-derived Mesenchymal Stem Cell Transplantation in Ischemic Cardiomyopathy” (UCMSC-Heart trial, NCT02439541) is currently recruiting patients with chronic heart ischemia and maximal tolerable angina to study the effect of the intracoronary infusion of MSC derived from umbilical cord blood (1 × 10^6). In this study, the primary outcome is safety in terms of MACE in the first year after treatment while secondary outcomes are exercise time, perfusion at SPECT, LVEF measured by echocardiography, and clinical improvements. MSC are also studied in the “MESenchymal cell therapy And Myocardial Ischemia with decreased left ventricular function” program (MESAMI2 trial, NCT02462330). The major aim of this project is to evaluate the effect of intramyocardial administration of autologous BM-derived MSC (preconditioned with the pineal hormone melatonin) using the NOGA XP system in patients suffering from chronic ischemic cardiomyopathy with a NYHA class II-IV and/or angina CCS class III-IV.

4. Conclusions

In this review, we have provided a comprehensive outlook on the status of the cardiac cell-based therapy field in the RA context. Although available data are still inconclusive as for definitive efficacy, we acknowledge signals are present, as discussed in this review, that imply this strategy is the most valuable advanced treatment option, as a tool to ameliorate prognosis “quod vitam et valutindem” in the therapeutic algorithm of patients suffering for RA.

Abbreviations

AT: Adipose tissue
BM: Bone marrow
CAD: Coronary artery disease
CCS: Canadian Cardiovascular Society
cMR: Cardiac magnetic resonance
CSC: Cardiac stem cells
LV: Left ventricular
LVEF: Left ventricular ejection fraction
MACE: Major adverse cardiac events
MET: Metabolic equivalent
MNC: Mononuclear cells
MSC: Mesenchymal stromal cells
MVO₂$: Maximal O₂ consumption
NTG: Nitroglycerin
PB: Peripheral blood
RA: Refractory angina
RCT: Randomized controlled trial
RWM: Regional wall motion
SAE: Serious adverse event
SAQ: Seattle Angina Questionnaire
SPECT: Single-photon emission computed tomography
SSS: Summed stress score
SRS: Summed rest score
SDS: Summed difference score
TET: Total exercise time.

Conflicts of Interest

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

This study was supported by the Italian Ministry of Health (RC2017 to Centro Cardiologico Monzino IRCCS). The authors thank Dr. Aoife Gowran for critical comments and editing assistance.

References

[1] C. Mannheimer, P. Camici, M. R. Chester et al., “The problem of chronic refractory angina. Report from the ESC Joint Study Group on the treatment of refractory angina,” European Heart Journal, vol. 23, no. 5, pp. 355–370, 2002.

[2] P. Andrèl, O. Ekre, L. Grip et al., ”Fatality, morbidity and quality of life in patients with refractory angina pectoris,” International Journal of Cardiology, vol. 147, no. 3, pp. 377–382, 2011.

[3] T. D. Henry, D. Satran, J. S. Hodges et al., “Long-term survival in patients with refractory angina,” European Heart Journal, vol. 34, no. 34, pp. 2683–2688, 2013.
[4] T. D. Henry, D. Satran, and E. M. Jolicoeur, “Treatment of refractory angina in patients not suitable for revascularization,” *Nature Reviews Cardiology*, vol. 11, no. 2, pp. 78–95, 2013.

[5] T. J. Povsic, S. Broderick, K. J. Anstrom et al., “Predictors of long-term clinical endpoints in patients with refractory angina,” *Journal of the American Heart Association*, vol. 4, no. 2, article e001287, 2015.

[6] M. McGillion, H. M. Arthur, A. Cook et al., “Management of patients with refractory angina: Canadian Cardiovascular Society/Canadian Pain Society Joint Guidelines,” *Canadian Journal of Cardiology*, vol. 28, no. 2, Supplement, pp. S20–S41, 2012.

[7] P. Nigro, B. Bassetti, L. Cavallotti, V. Catto, C. Carbucicchio, and G. Pompilio, “Cell therapy for heart disease after 15 years: unmet expectations,” *Pharmaceutical Research*, 2017.

[8] H. F. Tse, Y. L. Kwong, J. K. F. Chan, G. Lo, C. L. Ho, and C. P. Lau, “Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation,” *The Lancet*, vol. 361, no. 9351, pp. 47–49, 2003.

[9] N. Li, Y.-J. Yang, Q. Zhang, C. Jin, H. Wang, and H.-Y. Qian, “Stem cell therapy is a promising tool for refractory angina: a meta-analysis of randomized controlled trials,” *Canadian Journal of Cardiology*, vol. 29, no. 8, pp. 908–914, 2013.

[10] S. A. Fisher, C. Doree, S. J. Brunskill, A. Mathur, and E. Martin-Rendon, “Bone marrow stem cell treatment for ischemic heart disease in patients with no option of revascularization: a systematic review and meta-analysis,” *PLoS One*, vol. 8, no. 6, article e64669, 2013.

[11] A. R. Khan, T. A. Farid, A. Pathan et al., “Impact of cell therapy on myocardial perfusion and cardiovascular outcomes in patients with angina refractory to medical therapy,” *Circulation Research*, vol. 118, no. 6, pp. 984–993, 2016.

[12] T. J. Povsic, T. D. Henry, J. H. Traverse et al., “The RENEW trial: efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina,” *Circulation Research*, vol. 119, no. 15, pp. 1576–1585, 2016.

[13] W. Wojakowski, T. Jadczyk, A. Michalewska-Wudsonczyk et al., “Effects of transendocardial delivery of bone marrow–derived CD133+ cells on left ventricle perfusion and function in patients with refractory angina,” *Circulation Research*, vol. 120, no. 4, pp. 670–680, 2017.

[14] T. D. Henry, C. J. Pepine, C. R. Lambert et al., “The Athena trials: autologous adipose-derived regenerative cells for refractory chronic myocardial ischemia with left ventricular dysfunction,” *Catheterization and Cardiovascular Interventions*, vol. 89, no. 2, pp. 169–177, 2017.

[15] P. Jimenez-Quevedo, J. J. Gonzalez-Ferrer, M. Sabate et al., “Selected CD133+ progenitor cells to promote angiogenesis in patients with refractory angina: final results of the PROGENITOR randomized trial,” *Circulation Research*, vol. 115, no. 11, pp. 950–960, 2014.

[16] E. C. Perin, T. J. Willerson, C. J. Pepine et al., “Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial,” *JAMA*, vol. 307, no. 16, pp. 1717–1726, 2012.

[17] D. W. Losordo, T. D. Henry, C. Davidson et al., “Intramyocardial, autologous CD34+ cell therapy for refractory angina,” *Circulation Research*, vol. 109, no. 4, pp. 428–436, 2011.

[18] T. D. Henry, G. L. Schaer, J. H. Traverse et al., “Autologous CD34+ cell therapy for refractory angina: 2-year outcomes from the ACT34-CMI study,” *Cell Transplantation*, vol. 25, no. 9, pp. 1701–1711, 2016.

[19] P. V. Adler DS, H. Lazarus, R. Nair et al., “Safety and efficacy of bone marrow–derived autologous CD133+ stem cell therapy,” *Frontiers in Bioscience*, vol. E3, pp. 506–514, 2011.

[20] J. Babin-Ebell, H. H. Sievers, E. I. Chartis et al., “Transmyocardial laser revascularization combined with intramyocardial endothelial progenitor cell transplantation in patients with intractable ischemic heart disease ineligible for conventional revascularization: preliminary results in a highly selected small patient cohort,” *The Thoracic and Cardiovascular Surgeon*, vol. 58, no. 1, pp. 11–16, 2010.

[21] S. L. M. A. Beeres, J. J. Bax, P. Dibbets-Schneider et al., “Sustained effect of autologous bone marrow mononuclear cell injection in patients with refractory angina pectoris and chronic myocardial ischemia: twelve-month follow-up results,” *American Heart Journal*, vol. 152, no. 4, pp. 684.e11–684.e16, 2006.

[22] C. Briguori, B. Reimers, C. Sarais et al., “Direct intramyocardial percutaneous delivery of autologous bone marrow in patients with refractory myocardial angina,” *American Heart Journal*, vol. 151, no. 3, pp. 674–680, 2006.

[23] S. Fuchs, R. Kornowski, G. Weisz et al., “Safety and feasibility of transendocardial autologous bone marrow cell transplantation in patients with advanced heart disease,” *The American Journal of Cardiology*, vol. 97, no. 6, pp. 823–829, 2006.

[24] E. C. Perin, G. V. Silva, T. D. Henry et al., “A randomized study of transendocardial injection of autologous bone marrow mononuclear cells and cell function analysis in ischemic heart failure (FOCUS-HF),” *American Heart Journal*, vol. 161, no. 6, pp. 1078–1087.e3, 2011.

[25] T. Friis, M. Haack-Sørensen, A. B. Mathiasen et al., “Mesenchymal stromal cell derived endothelial progenitor treatment in patients with refractory angina,” *Scandinavian Cardiovascular Journal*, vol. 45, no. 3, pp. 161–168, 2011.

[26] M. Haack-Sørensen, T. Friis, A. B. Mathiasen et al., “Direct intramyocardial mesenchymal stromal cell injections in patients with severe refractory angina: one-year follow-up,” *Cell Transplantation*, vol. 22, no. 3, pp. 521–528, 2013.

[27] A. B. Mathiasen, M. Haack-Sørensen, E. Jorgensen, and J. Kastrup, “Autotransplantation of mesenchymal stromal cells from bone-marrow to heart in patients with severe stable coronary artery disease and refractory angina—final 3-year follow-up,” *International Journal of Cardiology*, vol. 170, no. 2, pp. 246–251, 2013.

[28] H. Klein, A. Ghodsizad, R. Marktanner et al., “Intramyocardial implantation of CD133+ stem cells improved cardiac function without bypass surgery,” *The Heart Surgery Forum*, vol. 10, no. 1, pp. E66–E69, 2007.

[29] F.-Y. Lee, Y.-L. Chen, P.-H. Sung et al., “Intracoronary transfusion of circulation-derived CD34+ cells improves left ventricular function in patients with end-stage diffuse coronary artery disease unsuitable for coronary intervention,” *Critical Care Medicine*, vol. 43, no. 10, pp. 2117–2132, 2015.

[30] D. W. Losordo, R. A. Schatz, C. J. White et al., “Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial,” *Circulation*, vol. 115, no. 25, pp. 3165–3172, 2007.
[31] I. Mann, S. F. Rodrigo, J. Van Ramshorst et al., “Repeated intramyocardial bone marrow cell injection in previously responding patients with refractory angina again improves myocardial perfusion, anginal complaints, and quality of life,” Circulation: Cardiovascular Interventions, vol. 8, article e002740, 2015.

[32] E. Pokushalov, A. Romanov, A. Chernyavsky et al., “Efficiency of intramyocardial injections of autologous bone marrow mononuclear cells in patients with ischemic heart failure: a randomized study,” Journal of Cardiovascular Translational Research, vol. 3, no. 2, pp. 160–168, 2010.

[33] G. Pompilio, G. Steinhoff, A. Liebold et al., “Direct minimally invasive intramyocardial injection of bone marrow-derived AC133+ stem cells in patients with refractory ischemia: preliminary results,” The Thoracic and Cardiovascular Surgeon, vol. 56, no. 2, pp. 71–76, 2008.

[34] E. C. Perin, R. Sanz-Ruiz, P. L. Sánchez et al., “Adipose-derived regenerative cells in patients with ischemic cardiomyopathy: the PRECISE trial,” American Heart Journal, vol. 168, no. 1, pp. 88–95.e2, 2014.

[35] H. F. Tse, S. Thambar, Y. L. Kwong et al., "Prospective randomized trial of direct endomyocardial implantation of bone marrow cells for treatment of severe coronary artery diseases (PROTECT-CAD trial)," European Heart Journal, vol. 28, no. 24, pp. 2998–3005, 2007.

[36] N. A. Hossne, A. L. Invitti, E. Buffolo et al., "Refractory angina cell therapy (ReACT) involving autologous bone marrow cells in patients without left ventricular dysfunction: a possible role for monocytes," Cell Transplantation, vol. 18, no. 12, pp. 1299–1310, 2009.

[37] N. A. Hossne, E. Cruz, E. Buffolo et al., "Long-term and sustained therapeutic results of a specific promonocyte cell formulation in refractory angina: ReACT* (refractory angina cell therapy) clinical update and cost-effective analysis," Cell Transplantation, vol. 24, no. 6, pp. 955–970, 2015.

[38] T. J. Povsic, C. Junge, A. Nada et al., “A phase 3, randomized, double-blinded, active-controlled, unblinded standard of care study assessing the efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina: design of the renew study,” American Heart Journal, vol. 165, no. 6, pp. 854–861.e2, 2013.

[39] J. Tuma, R. Fernández-Viña, A. Carrasco et al., “Safety and feasibility of percutaneous retrograde coronary sinus delivery of autologous bone marrow mononuclear cell transplantation in patients with chronic refractory angina,” Journal of Translational Medicine, vol. 9, no. 1, p. 183, 2011.

[40] J. Van Ramshorst, J. J. Bax, S. L. M. A. Beeres et al., “Intramyocardial bone marrow cell injection for chronic myocardial ischemia,” JAMA, vol. 301, no. 19, pp. 1997–2004, 2009.

[41] S. Wang, J. Cui, W. Peng, and M. Lu, “Intracoronary autologous CD34+ stem cell therapy for intractable angina,” Cardiology, vol. 117, no. 2, pp. 140–147, 2010.

[42] S. F. Rodrigo, J. Van Ramshorst, S. L. Beeres et al., “Intramyocardial injection of bone marrow mononuclear cells in chronic myocardial ischemia patients after previous placebo injection improves myocardial perfusion and anginal symptoms: an intra-patient comparison,” American Heart Journal, vol. 164, no. 5, pp. 771–778, 2012.

[43] E. C. Perin, K. M. Borow, G. V. Silva et al., “A phase II dose-escalation study of allogeneic mesenchymal precursor cells in patients with ischemic or nonischemic heart failure,” Circulation Research, vol. 117, no. 6, pp. 576–584, 2015.

[44] J. M. Hare, J. E. Fishman, G. Gerstenblith et al., “Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy,” JAMA, vol. 308, no. 22, pp. 2369–2379, 2012.

[45] J. M. Hare, J. H. Traverse, T. D. Henry et al., “A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction,” Journal of the American College of Cardiology, vol. 54, no. 24, pp. 2277–2286, 2009.

[46] C. Carbucicchio, M. Casella, V. Catto, B. Basseti, A. Bestetti, and G. Pompilio, “Case report novel application of 3-dimensional real-time cardiac imaging to guide stem cell-based therapy,” Canadian Journal of Cardiology, vol. 31, pp. 1073.e13–1073.e15, 2015.